Attach importance to standardized treatment of retinoblastoma to improve its treatment outcome_Chinese Journal of Ocular Fundus Diseases

Authors：

 Wei Wenbin , Zhou Nan

Beijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Ophthalmology & Visual Sciences Key Lab, Medical Artificial Intelligence Research and Verification Key Laboratory of the Ministry of Industry and Information Technology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China;

Corresponding author：

Wei Wenbin, Email: weiwenbintr@163.com

Keywords：

Retinoblastoma/therapy; Benchmarking; Editorial

DOI：

10.3760/cma.j.cn511434-20200520-00209

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

The treatment for retinoblastoma (RB) has been reached the stage of life-saving and vision-saving care. It is necessary to improve the survival rate and prolong the life time of RB children, retaining the eyeball and improving the quality of life. If the diagnosis is not timely and the treatment is inappropriate, the tumor recurrence, extraocular spread and metastasis of retinoblastoma will occur. The rate of eye protection and the survival chance of RB children will be reduced. With the continuous exploration of RB therapy and the emergence of new treatment methods, how to correctly select and evaluate these treatment methods and to adopt the most safe and effective treatment for RB children, to achieve long-term cure effect, is an important problem which clinicians need to consider.

Citation： Wei Wenbin, Zhou Nan. Attach importance to standardized treatment of retinoblastoma to improve its treatment outcome. Chinese Journal of Ocular Fundus Diseases, 2020, 36(6): 413-418. doi: 10.3760/cma.j.cn511434-20200520-00209 Copy

1.	Kivelä T. The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death[J]. Br J Ophthalmol, 2009, 93(9): 1129-1131. DOI: 10.1136/bjo.2008.150292.
2.	Sheilds CL, Mashayekhi A, Au AK, et al. The international classification of retinaoblastoma predicts chemoreduction success[J]. Ophthalmology, 2006, 113(12): 2276-2280. DOI: 10.1016/j.ophtha.2006.06.018.
3.	Helen D, Kimani K, Dimba EAO, et al. Retinoblastoma[J]. Lancet, 2012, 379(9824): 1436-1446. DOI: 10.1016/S0140-6736(11)61137-9.
4.	Reese AB, Ellsworth RM. The evaluation and current concept of retinoblastoma therapy[J]. Trans Am Acad Ophthalmol Otolaryngol, 1963, 67: 164-72.
5.	Linn Murphree A. Intraocular retinoblastoma: the case for a new group classification[J]. Ophthalmol Clin North Am, 2005, 18(1): 41-53. DOI: 10.1016/j.ohc.2004.11.003.
6.	Finger P, Harbour J, Murphree A, et al. Retinoblastoma[M]// Edge SB, Byrd DR, Compton CC, et al. AJCC Cancer Staging Manual. 8th ed. Berlin: Springer Science and Business Media, 2016: 561-568.
7.	Kivela T, Singh A. Information for authors project. 2011. http://eyecancerbig.com/EyeCaBIG/Journals_and_Societies.html (accessed Dec 13, 2011).
8.	Eng C, Li FP, Abramson DH, et al. Mortality from second tumors among long-term survivors of retinoblastoma[J]. J Natl Cancer Inst, 1993, 85(14): 1121-1128. DOI: 10.1093/jnci/85.14.1121.
9.	Abramson DH, Dunkel IJ, Brodie SE, et al. A phase Ⅰ/Ⅱ study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma[J]. Ophthalmology, 2008, 115(8): 1398-1404. DOI: 10.1016/j.ophtha.2007.12.014.
10.	Gobin YP, Dunkel IJ, Marr BP, et al. Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience[J]. Arch Opthalmol, 2011, 129(6): 732-737. DOI: 10.1001/archophthalmol.2011.5.
11.	Sheilds CL, Ramasubramanian A, Thangappan A, et al. Chemoreduction for group E retinoblastoma: comparison of chemoreduction alone vs chemoreduction plus low dose external radiotherapy in 76 eyes[J]. Ophthalmology, 2009, 116(3): 544-551. DOI: 10.1016/j.ophtha.2008.10.014.
12.	Schaiquevich P, Cediliano A, Millan N, et al. Intra-arterial chemotherapy is more effective than sequential periocular and intravenous chemotherapy as salvage treatment for relaplsed retinoblastoma[J]. Pediatr Blood Cancer, 2013, 60(5): 766-770. DOI: 10.1002/pbc.24356.
13.	Peterson EC, Elhammady MS, Ouintero-Wolfe S, et al. Selective ophthalmic artery infusion of chemotherapy for advanced intraocular retinoblastoma: initial experience with 17 tumors[J]. J Neurosurg, 2011, 121(9): 1810-1817. DOI: 10.3171/2011.1.JNS10466.
14.	Amemiya T, Yoshida H, Ishigooka H. Vitreous seeds in retinoblastoma, clinical significance and ultrastructure[J]. Albrecht Von Graefes Arch Klin Exp Ophthalmol, 1979, 211(3): 205-213. DOI: 10.1007/BF02387425.
15.	Francis JH, Schaiquevich P, Buitrago E, et al. Local and systemic toxicity of intravitreal melphalan for vitreous seeding in tetinoblastoma: a preclinical and clinical study[J]. Ophthalmology, 2014, 121(9): 1810-1817. DOI: 10.1016/j.ophtha.2014.03.028.
16.	Munier FL, Gaillard MC, Balmer A, et al. Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications[J]. Br J Opthalmol, 2012, 96(8): 1078-1083. DOI: 10.1136/bjophthalmol-2011-301450.
17.	McDaid C, Hartley S, Bagnall AM, et al. Systematic review of effectiveness of different treatments for childhood retinoblastoma[J]. Health Technol Assess, 2005, 9: 1-145. DOI: 10.3310/hta9480.
18.	Shields CL, Shields JA. Basic understanding of current classification and management of retinoblastoma[J]. Curr Opin Opthalmol, 2006, 17(3): 228-234. DOI: 10.1097/01.icu.0000193079.55240.18.
19.	Kaliki S, Shields CL. Retinoblastoma: achieving new standards with methods of chemotherapy[J]. Indian J Ophthalmol, 2015, 63(2): 103-109. DOI: 10.4103/0301-4738.154369.
20.	Shields CL, Honavar S, Shields JA, et al. Vitrectomy in eyes with unsuspected retinoblastoma[J]. Ophthalmology, 2000, 107(12): 2250-2255. DOI: 10.1016/s0161-6420(00)00427-9.
21.	Stevenson KE, Hungerford J, Garner A. Local extraocular extension of retinoblastoma following intraocular surgery[J]. Br J Ophthalmol, 1989, 73(9): 739-742. DOI: 10.1136/bjo.73.9.739.
22.	Zhao J, Li Q, Wu S, et al. Pars plana vitrectomy and endoresection of refractory intraocular retinoblastoma[J]. Ophthalmology, 2018, 125(2): 320-322. DOI: 10.1016/j.ophtha.2017.10.015.
23.	Chawla B, Hada M, Seth R, et al. Trabeculectomy in eyes with unsuspected retinoblastoma[J]. Ophthalmic Genet, 2016, 37(4): 437-440. DOI: 10.3109/13816810.2015.1126610.
24.	中华医学会眼科学分会眼底病学组, 中华医学会儿科学分会眼科学组, 中华医学会眼科学分会眼整形眼眶病学组. 中国视网膜母细胞瘤诊断和治疗指南(2019年)[J]. 中华眼科杂志, 2019, 55(10): 726-738.DOI: 10.3760/cma.j.issn.0412-4081.2019.10.003.Ocular Fundus Diseases Group of Ophthalmological Society in Chinese Medical Association, Ophthalmology Group of Pediatric Society in Chinese Medical Association, Ophthalmic Orthopedics and Orbitology Group of Ophthalmological Society in Chinese Medical Association. Guidelines for diagnosis and treatment of retinoblastoma in China (2019)[J]. Chin J Ophthalmol, 2019, 55(10): 726-738.DOI: 10.3760/cma.j.issn.0412-4081.2019.10.003.
25.	中华医学会眼科学分会眼整形眼眶病学组. 中国单侧眼内期视网膜母细胞瘤诊疗专家共识(2019年)[J]. 中华眼科杂志, 2019, 55(4):250-254. DOI:10.3760/cma.j.issn.0412-4081.2019.04.003.Ophthalmic Orthopedics and Orbitology Section of Chinese Ophthalmological Society, Chinese Medical Association. Consensus of Chinese experts on diagnosis and treatment of unilateral intraocular stage retinoblastoma[J]. Chin J Ophthalmol, 2019, 55(4):250-254. DOI:10.3760/cma.j.issn.0412-4081.2019.04.003.

1. Kivelä T. The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death[J]. Br J Ophthalmol, 2009, 93(9): 1129-1131. DOI: 10.1136/bjo.2008.150292.
2. Sheilds CL, Mashayekhi A, Au AK, et al. The international classification of retinaoblastoma predicts chemoreduction success[J]. Ophthalmology, 2006, 113(12): 2276-2280. DOI: 10.1016/j.ophtha.2006.06.018.
3. Helen D, Kimani K, Dimba EAO, et al. Retinoblastoma[J]. Lancet, 2012, 379(9824): 1436-1446. DOI: 10.1016/S0140-6736(11)61137-9.
4. Reese AB, Ellsworth RM. The evaluation and current concept of retinoblastoma therapy[J]. Trans Am Acad Ophthalmol Otolaryngol, 1963, 67: 164-72.
5. Linn Murphree A. Intraocular retinoblastoma: the case for a new group classification[J]. Ophthalmol Clin North Am, 2005, 18(1): 41-53. DOI: 10.1016/j.ohc.2004.11.003.
6. Finger P, Harbour J, Murphree A, et al. Retinoblastoma[M]// Edge SB, Byrd DR, Compton CC, et al. AJCC Cancer Staging Manual. 8th ed. Berlin: Springer Science and Business Media, 2016: 561-568.
7. Kivela T, Singh A. Information for authors project. 2011. http://eyecancerbig.com/EyeCaBIG/Journals_and_Societies.html (accessed Dec 13, 2011).
8. Eng C, Li FP, Abramson DH, et al. Mortality from second tumors among long-term survivors of retinoblastoma[J]. J Natl Cancer Inst, 1993, 85(14): 1121-1128. DOI: 10.1093/jnci/85.14.1121.
9. Abramson DH, Dunkel IJ, Brodie SE, et al. A phase Ⅰ/Ⅱ study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma[J]. Ophthalmology, 2008, 115(8): 1398-1404. DOI: 10.1016/j.ophtha.2007.12.014.
10. Gobin YP, Dunkel IJ, Marr BP, et al. Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience[J]. Arch Opthalmol, 2011, 129(6): 732-737. DOI: 10.1001/archophthalmol.2011.5.
11. Sheilds CL, Ramasubramanian A, Thangappan A, et al. Chemoreduction for group E retinoblastoma: comparison of chemoreduction alone vs chemoreduction plus low dose external radiotherapy in 76 eyes[J]. Ophthalmology, 2009, 116(3): 544-551. DOI: 10.1016/j.ophtha.2008.10.014.
12. Schaiquevich P, Cediliano A, Millan N, et al. Intra-arterial chemotherapy is more effective than sequential periocular and intravenous chemotherapy as salvage treatment for relaplsed retinoblastoma[J]. Pediatr Blood Cancer, 2013, 60(5): 766-770. DOI: 10.1002/pbc.24356.
13. Peterson EC, Elhammady MS, Ouintero-Wolfe S, et al. Selective ophthalmic artery infusion of chemotherapy for advanced intraocular retinoblastoma: initial experience with 17 tumors[J]. J Neurosurg, 2011, 121(9): 1810-1817. DOI: 10.3171/2011.1.JNS10466.
14. Amemiya T, Yoshida H, Ishigooka H. Vitreous seeds in retinoblastoma, clinical significance and ultrastructure[J]. Albrecht Von Graefes Arch Klin Exp Ophthalmol, 1979, 211(3): 205-213. DOI: 10.1007/BF02387425.
15. Francis JH, Schaiquevich P, Buitrago E, et al. Local and systemic toxicity of intravitreal melphalan for vitreous seeding in tetinoblastoma: a preclinical and clinical study[J]. Ophthalmology, 2014, 121(9): 1810-1817. DOI: 10.1016/j.ophtha.2014.03.028.
16. Munier FL, Gaillard MC, Balmer A, et al. Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications[J]. Br J Opthalmol, 2012, 96(8): 1078-1083. DOI: 10.1136/bjophthalmol-2011-301450.
17. McDaid C, Hartley S, Bagnall AM, et al. Systematic review of effectiveness of different treatments for childhood retinoblastoma[J]. Health Technol Assess, 2005, 9: 1-145. DOI: 10.3310/hta9480.
18. Shields CL, Shields JA. Basic understanding of current classification and management of retinoblastoma[J]. Curr Opin Opthalmol, 2006, 17(3): 228-234. DOI: 10.1097/01.icu.0000193079.55240.18.
19. Kaliki S, Shields CL. Retinoblastoma: achieving new standards with methods of chemotherapy[J]. Indian J Ophthalmol, 2015, 63(2): 103-109. DOI: 10.4103/0301-4738.154369.
20. Shields CL, Honavar S, Shields JA, et al. Vitrectomy in eyes with unsuspected retinoblastoma[J]. Ophthalmology, 2000, 107(12): 2250-2255. DOI: 10.1016/s0161-6420(00)00427-9.
21. Stevenson KE, Hungerford J, Garner A. Local extraocular extension of retinoblastoma following intraocular surgery[J]. Br J Ophthalmol, 1989, 73(9): 739-742. DOI: 10.1136/bjo.73.9.739.
22. Zhao J, Li Q, Wu S, et al. Pars plana vitrectomy and endoresection of refractory intraocular retinoblastoma[J]. Ophthalmology, 2018, 125(2): 320-322. DOI: 10.1016/j.ophtha.2017.10.015.
23. Chawla B, Hada M, Seth R, et al. Trabeculectomy in eyes with unsuspected retinoblastoma[J]. Ophthalmic Genet, 2016, 37(4): 437-440. DOI: 10.3109/13816810.2015.1126610.
24. 中华医学会眼科学分会眼底病学组, 中华医学会儿科学分会眼科学组, 中华医学会眼科学分会眼整形眼眶病学组. 中国视网膜母细胞瘤诊断和治疗指南(2019年)[J]. 中华眼科杂志, 2019, 55(10): 726-738.DOI: 10.3760/cma.j.issn.0412-4081.2019.10.003.Ocular Fundus Diseases Group of Ophthalmological Society in Chinese Medical Association, Ophthalmology Group of Pediatric Society in Chinese Medical Association, Ophthalmic Orthopedics and Orbitology Group of Ophthalmological Society in Chinese Medical Association. Guidelines for diagnosis and treatment of retinoblastoma in China (2019)[J]. Chin J Ophthalmol, 2019, 55(10): 726-738.DOI: 10.3760/cma.j.issn.0412-4081.2019.10.003.
25. 中华医学会眼科学分会眼整形眼眶病学组. 中国单侧眼内期视网膜母细胞瘤诊疗专家共识(2019年)[J]. 中华眼科杂志, 2019, 55(4):250-254. DOI:10.3760/cma.j.issn.0412-4081.2019.04.003.Ophthalmic Orthopedics and Orbitology Section of Chinese Ophthalmological Society, Chinese Medical Association. Consensus of Chinese experts on diagnosis and treatment of unilateral intraocular stage retinoblastoma[J]. Chin J Ophthalmol, 2019, 55(4):250-254. DOI:10.3760/cma.j.issn.0412-4081.2019.04.003.

Next Article
Retrospective clinical study on the comprehensive treatment of retinoblastoma

Chinese Journal of Ocular Fundus Diseases

Attach importance to standardized treatment of retinoblastoma to improve its treatment outcome

Abstract Full text Figures/Tables Video References Cited by

Next Article

Format

Content